Exelixis buoyed after FDA cancels 'cabo' panel; Bayer adds new app for blockbuster hopeful regorafenib;

Conversations on Twitter :

Analysts and experts dissect Exelexis chances after announcement that FDA's advisory panel no longer plans to discuss its thyroid cancer drug cabozantinib at November meeting here, here and here.
Great news about FDA approval of rare form of brain tumor in kids. Conversation started by @JohnCFierce
Large financings don't necessarily translate into large returns. Here is a discussion around an article that looked at the biggest financings of 2007 where 50% failed.

 @FierceBiotech: XBiotech hatches big plans for Austin campus. Item | Follow @FierceBiotech

 @JohnCFierce: At long last, Ironwood gets its OK, shifts to commercialization alongside development. News | Follow @JohnCFierce

> Shares of Exelixis ($EXEL) surged after the company alerted investors that the FDA was canceling a planned panel review for cabozantinib as a new therapy for thyroid cancer. Analysts interpreted the move as an indication of the FDA's confidence in the drug, indicating a better potential for approval. Story

> Bayer has filed for approval of its blockbuster contender regorafenib as a treatment for gastrointestinal cancer. The drug has already been filed for metastatic colorectal cancer. Story

> The preclinical CRO Charles River has bought out Accugenix for $17 million, adding its testing technology used in drug and device development. Report

Pharma News

 @FiercePharma: Two drugmakers hit the Forbes "Fab 50" in Asia: Australia's CSL and India's Sun Pharma. Item | Follow @FiercePharma

> Novartis begs vets for loyalty through animal drug shortages. Article

> Avastin tops list of most-requested cancer meds in U.K. Report

> FDA flags cataract risk in kids using Vertex's Kalydeco. Story

Medical Device News

 @FierceMedDev: Bacterin International, a maker of bone graft material and antimicrobial coatings, won $25M in financing from OrbiMed. Release | Follow @FierceMedDev

 @MarkHFierce: BSX is slashing more jobs and splitting its cardio business in two--undoing changes enacted by the old CEO. More | Follow @MarkHFierce

 @DamianFierce: Baxter is recalling four Automix devices over a deadly malfunction risk. The FDA has labeled it a Class I. News | Follow @DamianFierce

> Zynex gets 510(k) for urinary incontinence device. News

> MDxHealth's revenues soar, losses deepen in H1. Item

Pharma Manufacturing News

 @EricPFierce: Hospira goes back to Orchid, picks up API plant, R&D center for $200 million. Good news tainted a bit by FDA warning. Story | Follow @EricPFierce

> Closed plants lead Novartis to plead for vet loyalty. Story

> Claris squares off against former partners in U.S. injectables market. Article

> Scots reject GSK wind turbines; tidal turbines up next. Story

Vaccines News

 @AlisonBFierce: What does AstraZeneca's new CEO mean to vaccinemaker MedImmune? More | Follow @AlisonBFierce

> S. Korea, Sweden partner up to find Alzheimer's vaccine. Item

> West Nile virus breaks out in the South. News

> CSL nets closeout letter after FDA violations. More

> Flu adjuvant adds promise to vaccine. Report

And Finally... Investigators at the Karolinska Institute have produced fresh evidence to demonstrate that chocolate can guard against the risk of a stroke. Article